CytomX Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

CTMX$1.980.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

CONDENSED STATEMENTS OF OPERA TIONS AND COMPREHENSIVE INCOME (LOSS)

(in thousands, except share and per share data)

Three Months Ended · Nine Months Ended
	September 30,		September 30,
	2024	2023	2024	2023
Revenues	$33,432	$26,384	$100,010	$74,607
Operating expenses:
Research and development	21,368	16,448	68,592	58,294
General and administrative	7,953	6,813	24,102	22,191
Total operating expenses	29,321	23,261	92,694	80,485
Income (loss) from operations	4,111	3,123	7,316	(5,878)
Interest income	1,693	2,699	5,858	7,334
Other (expense) income, net	(7)	(7)	(19)	(39)
Income before income taxes	5,797	5,815	13,155	1,417
Provision for income taxes	61	2,823	162	2,823
Net income (loss)	5,736	2,992	12,993	(1,406)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net of tax	44	(98)	(55)	(73)
Total comprehensive income (loss)	$5,780	$2,894	$12,938	$(1,479)
Net income (loss) per share:
Basic	$0.07	$0.04	$0.15	$(0.02)
Diluted	$0.07	$0.04	$0.15	$(0.02)
Shares used to compute net income (loss) per share
Basic	85,093,227	80,731,951	84,005,093	71,225,433
Diluted	85,204,709	80,991,722	84,428,843	71,225,433

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.